Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gentamicin dosage regimen based on serum creatinine concentration.

E Malvino1, D Goldenberg, R Giniger

  • 1Special Care Division, Policlínica Bancaria, Buenos Aires, Argentina.

Chemotherapy
|January 1, 1987
PubMed
Summary

This study developed a serum creatinine correction factor to safely adjust gentamicin dosing intervals when drug monitoring is unavailable. This method successfully maintained therapeutic drug levels, avoiding toxicity in patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sagittal balance and intervertebral disc composition in patients with low back pain.

Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas·2022
Same author

Ethanol and isopropanol inactivation of human coronavirus on hard surfaces.

The Journal of hospital infection·2020
Same author

Body composition and bone status in relation to microvascular damage in systemic sclerosis patients.

Journal of endocrinological investigation·2020
Same author

Potential role of clodronate in painful hip prosthesis.

Journal of biological regulators and homeostatic agents·2020
Same author

Correction to: Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial.

Cancer chemotherapy and pharmacology·2019
Same author

First-line panitumumab plus docetaxel and cisplatin in advanced gastric and gastro-oesophageal junction adenocarcinoma: results of a phase II trial.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2019

Area of Science:

  • Pharmacology
  • Nephrology
  • Clinical Pharmacy

Background:

  • Gentamicin, an aminoglycoside antibiotic, requires careful dosing to prevent toxicity.
  • Therapeutic drug monitoring is crucial but often unavailable, necessitating alternative dosing strategies.

Purpose of the Study:

  • To establish a reliable method for adjusting gentamicin dosage intervals based on serum creatinine levels.
  • To evaluate the efficacy of a calculated correction factor for serum creatinine in optimizing gentamicin therapy.

Main Methods:

  • A regression analysis was performed on serum creatinine (SCr) and gentamicin half-life (T1/2) in 35 patients.
  • A predictive formula (log T1/2 = log 2.28 + 1.45 log SCr) was derived from this data.
  • A second group of 18 patients received adjusted gentamicin doses based on this formula, with intervals targeting 3 T1/2.

Related Experiment Videos

Main Results:

  • A strong correlation (r=0.90, p<0.01) was found between SCr and T1/2.
  • The established formula accurately predicted gentamicin half-life across varying SCr levels.
  • All patients in the second group achieved trough serum gentamicin concentrations within the desired therapeutic range.

Conclusions:

  • A serum creatinine-based correction factor provides an effective means to adjust gentamicin dosing intervals.
  • This approach is valuable for preventing gentamicin toxicity in settings lacking drug monitoring capabilities.
  • Optimized dosing intervals ensure therapeutic efficacy while minimizing adverse effects.